## nature portfolio

Corresponding author(s):	Jaeyun Kim
Last updated by author(s):	May 2, 2022

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

٠.	+~	.+-	ıstı	
_	_			II 🔍
_	LU			

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Software and code
Policy information about <u>availability of computer code</u>

Data collection No custom codes and special softwares were used.

Data analysis No custom codes and special softwares were used.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

## Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data is available in main text and supplementary information. The raw data is available from the corresponding author upon reasonable request.

## Life sciences study design

Commonly misidentified lines (See <u>ICLAC</u> register)

	iccs stad	y acsign		
All studies must dis	sclose on these point	ts even when the disclosure is negative.		
Sample size	No statistical method was used to predetermine sample size in cell toxicity study of hydrogels (Supplementary Figure 14).			
Data exclusions	No data were exclude	o data were excluded from the analyses.		
Replication	Almost measuremen	asurements were performed at least twice.		
Randomization	No randomization wa	tion was used.		
Blinding	No blinding was invo	lved.		
We require informati	ion from authors about	cific materials, systems and methods  some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
,	perimental syste			
Animals an Human res Clinical dat	cell lines logy and archaeology and other organisms search participants ta esearch of concern	n/a Involved in the study    ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   ChIP-seq   Involved in the study   Involved in the study   ChIP-seq   Involved in the study   In		
Policy information	about <u>cell lines</u>			
Cell line source(s)	L6 m	nyoblast cell		
Authentication	The	cell for cytotoxicity test of the hydrogel was not authenticated.		
Mycoplasma conta	mination The	cell was not tested for mycoplasma contamination.		

No misidentified cell lines were used.